Year None202320222021202020192018201720162015201420132012 09.24.2013 Ophthotech Corporation Prices Initial Public Offering 08.29.2013 Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD 08.15.2013 Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering 05.29.2013 Funding to Develop the First Therapy to Show Superior Efficacy Over the Current Standard of Care 01.03.2013 Ophthotech to Present at 31st Annual J.P. Morgan Healthcare Conference 10.24.2012 Positive Results from Phase 2b Study of Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ to be Presented at AAO Retina Subspecialty Day 06.13.2012 Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial 01.03.2012 Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous … Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Current page 28
